CD274 and lung carcinoma: Patients receiving only systemic supportive therapy or those who are resistant to hormonal or biological agents are likely to derive less benefit from treatment (39).In patients with gastrointestinal metastases originating from lung cancer, the high expression levels of PD-L1 may represent a viable target for immune checkpoint inhibitor therapy (40).